Symposia
Saturday, 18 September – 17:35 – 18:35 CET
ISS Janssen Satellite Symposium – Is “Standard of Care” a thing in the past in CLL?
| 17:35 | 5 mins | Introduction
| Chair: John Gribben |
|
| 17:40 | 15 mins | No, “Standard of Care” is not a thing of the past in CLL | Carol Moreno |
| 17:50 | 15 mins | Yes, “Standard of Care” is a thing of the past in CLL | Paolo Ghia |
| 18:05 | 15 mins | Novel Agents: No longer novel? | Steven Coutre |
| 18:15 | 15 mins | Panel discussion | All Faculty |
| 18:30 | 5 mins | Closing Remarks | |
| 18:35 | Adjourn |
Sunday, 19 September – 13:45 – 14:45 CEST
ISS BeiGene Satellite Symposium - Evolving Role of BTK Inhibitors in R/R CLL – A Rational Approach to Improving Patient Outcomes
| 13:45 | 4 mins | Welcome, introduction and objectives
| Chair: Anna Schuh |
|
| 13:49 | 10 mins | A pharmacologist’s view on the rationale for using different BTK inhibitors for R/R CLL | Federico Pea |
| 13:59 | 10 mins | Evolving strategies with next generation BTK inhibitors as treatment for R/R CLL patients | Wojciech Jurczak |
| 14:09 | 12 mins | 2 Patient Case Reports in R/R CLL | Othman Al-Sawaf |
| 14:21 | 10 mins | Panel discussion | All Faculty |
| 14:31 | 14 mins | Audience Q&A | All Faculty |
| 14:45 | Adjourn |
Sunday, 19 September – 17:00 – 18:00 CEST
ISS AbbVie Satellite Symposium CLARIFYING COMPLEXITY IN CLL: Optimal management of patients with challenging molecular subtypes
| 17:00 | 5 mins | Welcome and introduction
| Chair: Barbara Eichhorst |
|
| 17:05 | 15 mins | Understanding challenging molecular subtypes in CLL | Anna Schuh |
| 17:20 | 15 mins | Management of CLL with challenging molecular subtypes | Barbara Eichhorst |
| 17:35 | 15 mins | Strategies to address unmet needs in challenging molecular subtypes |
Matthew Davids |
| 17:50 | 10 mins | Audience Q&A / close | All speakers |
| 18:00 | Adjourn |
Monday, 20 September – 15:55 – 16:55 CEST
ISS AstraZeneca Satellite Symposium Targeting BTK in CLL: Expert Guidance on Selecting Single-Agent and Combination Therapy
| 15:55 | 5 mins | Welcome, Introduction, Polling Questions
| Chair: Richard Furman |
|
| 16:00 | 10 mins | The Current Role of BTK Inhibitors in CLL | Richard Furman |
| 16:10 | 35 mins | Case Discussions: Practical Guidance on Selecting BTK inhibitor Therapy in CLL | All Faculty |
| 16:45 | 10 mins | Summary, Final Thought, Audience Q&A | |
| 16:55 | Adjourn |